NanoViricides Reports That Its CEO Was Interviewed On The RedChip Money Report Program On Fox Business News TV Channel Yesterday Evening
NanoViricides, Inc. (OTC BB:
(the "Company"), reports that a video interview with its CEO, Eugene
Seymour, MD, MPH, was broadcast on the Fox Business News TV channel (FBN
TV) today at 1:00am EDT.
NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), reports that a video interview with its CEO, Eugene Seymour, MD, MPH, was broadcast on the Fox Business News TV channel (FBN TV) today at 1:00am EDT. A link to a video of this interview will be made available on the Company’s website next week. This unsolicited interview was conducted by David Gentry of “The RedChip Money Report” of the Red Chip Companies, an international small cap research, investor relations and media company. The broadcast was listed as a “paid program” in the FBN TV guide. The Company does not have any formal business engagement with RedChip at present. RedChip has chosen to broadcast its small caps company research interviews on FBN since Fox Business News is a premier business network reaching more than 65 million homes nationwide. Among all cable networks, Fox Business News' viewership ranks second only to Bloomberg in affluence. The discussion centered around FluCide™, the Company’s broad-spectrum anti-influenza drug, that addresses a potential $25B annual market. Dr. Seymour went on to explain that “we have essentially cured mice of influenza,” referring to our highly successful animal studies demonstrating extremely high efficacy of FluCide against various types of influenza viruses, such as H1N1 and H3N2. In highly lethal animal models with extremely high inoculation doses of the influenza viruses of these different types, the Company has observed its lead candidate to reduce viral load by 100-fold to 1,000-fold (2 to 3 logs), whereas, in the same studies, Tamiflu, the standard of care, resulted in a reduction in viral load by only a factor of 2-to-8-fold (0.2 to 0.8 logs) at the same time points, as the Company has reported previously in various press releases. The extent of remaining viral load was extremely small in FluCide-treated animals, and continued to be small through the entire 21 day study span in one of the studies. Based on these studies, and peripheral knowledge of influenza human clinical trials of various drugs, the Company believes that FluCide may be a potential cure for influenza.